iBio, Inc., a biotech innovator and biologics contract development and manufacturing organization (CDMO), has entered into its first Statement of Work (SoW) under a Master Services Agreement with Belgium-based ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming System.
 
The fusion proteins, called atbodies, are being designed for the treatment of cancers. iBio will develop a manufacturing process and assays for select atbodies per the SoW.
 
“We are pleased to be chosen as the process development and manufacturing partner for atbtherapeutics, whose platform technology offers a unique approach for hard-to-treat hematological malignancies and solid tumors,” said Tom Isett, chairman and chief executive officer, iBio. “We are looking forward to helping atbtherapeutics rapidly build a scalable manufacturing process so that its atbody drug candidates may quickly reach the clinic and begin to realize their potential in oncology.”
 
Bertrand Magy, CEO of atbtherapeutics, said, “We are thrilled to be working with iBio, a high-quality, customer-focused CDMO whose proven expertise should be highly valuable as we prepare for our first safety trials. With iBio’s support, we believe we will be able to rapidly progress toward the clinic with our lead product candidates for the treatment of cancer.”